

The Manager  
Company Announcement Office  
ASX Limited

## COMPLETION OF SHARE PURCHASE PLAN RAISING \$517,450

**Adelaide, 25 July 2014:** LBT Innovations Limited (ASX:LBT) (**Company**) advises that the share purchase plan described in the Offer Booklet dated 27 June 2014 (**SPP**) closed on 17 July 2014 raising \$517,450 before expenses.

The SPP follows the \$1.5 million placement to institutional and sophisticated investors and related parties of the Company which was announced on 18 June 2014. Overall the combined placement and SPP has raised \$2.018 million subject to the approval of the second tranche placement shares at the EGM scheduled for 1<sup>st</sup> August 2014.

The Company has accepted all valid applications received for the SPP and will issue 3,832,944 ordinary shares at an issue price of \$0.135 per share, raising \$517,450.

In conjunction with the Placement, the additional \$2.018 million raised will secure funding for the APAS® clinical trials and allow the initiation of the first phase of the proposed technology development programme for Woundvue™, which is based on LBT's intelligent imaging platform.

All new shares relating to the SPP are expected to be allotted on 7 August 2014 and the statements of holdings for these new shares are expected to be despatched on 12 August 2014 at the same time as the second tranche placement shares

The directors of the Company wish to thank all shareholders who participated in the SPP.

– ENDS –

### About LBT Innovations

LBT Innovations (LBT) is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company has two breakthrough products in microbiology automation: PREVI® Isola, which provides automation of culture plate streaking, and APAS®, a breakthrough in automated culture plate reading, interpretation and reporting. LBT also has a third product in development, Woundvue™, a proposed automation solution to assist in the management of chronic wounds.

LBT has an exclusive global licence agreement with French diagnostics company bioMérieux to manufacture and market PREVI® Isola. LBT receives ongoing royalty payments for PREVI Isola, which has been installed in clinical laboratories around the world. LBT's APAS® technology (the Automated Plate Assessment System) is nearing market. Based upon LBT's innovative intelligent image interpretation platform, APAS specifically addresses the automated imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a Joint Venture with Hettich AG Switzerland to drive the commercial development and global distribution of APAS instrumentation and software products.

For more information, see [www.lbtinnovations.com](http://www.lbtinnovations.com)

### CONTACTS

LBT Innovations	Media Relations
Lusia Guthrie CEO Tel: +61 (0)8 8227 1555 E: <a href="mailto:info@lbtinnovations.com">info@lbtinnovations.com</a>	Rudi Michelson Monsoon Communications Tel: +61 (0)3 9620 3333 E: <a href="mailto:rudim@monsoon.com.au">rudim@monsoon.com.au</a>